Eiger Gets OK On Ch. 11 Drug Sale After Tripling Initial Bid

By Alex Wittenberg · June 26, 2024, 8:47 PM EDT

A Texas bankruptcy judge on Wednesday approved Eiger BioPharmaceuticals' $35.1 million sale of its Avexitide product, after the drug company more than tripled an initial bid for the metabolic-disease treatment during...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Case Information

Case Title

Eiger BioPharmaceuticals, Inc.

Case Number

Court

Texas Northern

Nature of Suit

Date Filed

April 01, 2024

Recent Articles By Alex

November 01, 2024
Buca Di Beppo Gets OK On $27M Sale To Main Street Capital
October 30, 2024
Implant Maker Exactech Can Tap $85M DIP After Cutting Fees
October 29, 2024
MVP: Latham's George Davis
October 29, 2024
PE-Owned Implant Maker Plagued By Lawsuits Hits Ch. 11
October 28, 2024
Ex-Judge Can't Shield Bank Docs; Tupperware Agrees To Sale
October 25, 2024
Incora To Exit Ch. 11 With Uptier Fight Headed To Appeal
October 23, 2024
American Tire Hits Ch. 11 Again With $1.9B Of Debt, Sale Plan
October 21, 2024
Keeping Track Of The Catholic Diocese Bankruptcy Cases
October 16, 2024
Big Lots Protections For $760M Bid Draw US Trustee Protest
October 15, 2024
Sacklers Say Opioid Claims Can't Undo Purdue Transfers